---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-146135"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2025-06-25T23:59:59+00:00"
generated_at: "2026-05-18T19:49:09.636925+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sanofi to advance Kymera's KT-485 IRAK4 degrader; $20M milestone achieved

## Summary
- Sanofi selects KT-485 for Phase 1 testing in immuno-inflammatory diseases, expected to start next year; KT-474 will not advance.
- KT-485 showed improved potency, selectivity, and safety profile vs KT-474 in preclinical testing.
- Kymera earned a $20M milestone in Q2 2025 for preclinical activities on KT-485.
- Kymera eligible for up to $975M in milestones plus double-digit royalties; may opt-in to 50/50 U.S. profit share.
- Sanofi exercised participation election right for IRAK4 target under collaboration agreement.

## SEC filing metadata
- accession: 0001193125-25-146135
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2025-06-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312525146135/0001193125-25-146135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312525146135/d89458d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-146135
- JSON: https://secwatch.observer/filing/0001193125-25-146135.json
- Plain text: https://secwatch.observer/filing/0001193125-25-146135.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.